Adherence to antibiotic guidelines for erysipelas or cellulitis is associated with a favorable outcome
- 67 Downloads
Outside areas of S. aureus strains resistant to methicillin (MRSA) in the community, no studies showed a relationship between the treatment for erysipelas or cellulitis and the outcome. We aimed to measure the impact of an internal therapeutic protocol, based on national guidelines on patients’ outcome. This study was based on the dashboard of the infectious diseases department, which prospectively includes 28 parameters for all admitted patients. We included community-acquired erysipelas and cellulitis; exclusion criteria were abscesses at admission; ear, nose, throat, or dental cellulitis; pyomyositis; and length of stay ≤ 2 days. Adherence to guidelines was defined by the use of amoxicillin, amoxicillin/clavulanic acid, clindamycin, or pristinamycin, alone or in combination or successively. A poor outcome was defined by surgical procedure or intensive care requirement or death occurring after 5 days or more of antibiotic therapy. From July 2005 to June 2017, 630 cases of erysipelas or cellulitis were included. Blood cultures performed in 567 patients (90%) were positive in 39 cases (6.9%). Adherence rate to guidelines was 65% (410 cases). A poor outcome was recorded in 54 (8.5%) patients, less frequently in case of adherence to guidelines: 26/410 (6.3%) vs 28/220 (12.7%), p = 0.007. In logistic regression analysis, two risk factors were associated with a poor outcome: peripheral arterial disease, AOR 4.80 (2.20–10.49); and bacteremia, AOR 5.21 (2.31–11.76), while guideline adherence was the only modifiable protective factor, OR 0.48 (0.26–0.89). In erysipelas and cellulitis, adherence to guidelines was associated with a favorable outcome.
KeywordsErysipelas Cellulitis SSTI Antibiotic therapy Guidelines Outcome
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Observational studies do not require ethical approval in France. Antimicrobial stewardship is promoted by the French National Health Agency. Internal dashboard is declared to French Data Protection Authority, number 1430722.
Patients or their relatives provided their written consent for digitization of their personal data for hospitalization purposes.
- 1.Erysipèle et fasciite nécrosante. Prise en charge. Conférence de consensus (2000) Med Mal Inf 30(Suppl 4):252–72Google Scholar
- 3.Food and Drug Administration (2013) Guidance for industry: acute bacterial skin and skin structure infections developing drugs for treatment. www.fda.gov/downloads/Drugs/Guidances/ucm071185.pdf. Accessed 24 August 2016
- 7.Lazzarini L, Conti E, Tositti G, Lalla F (2005) Erysipelas and cellulitis: clinical and microbiological spectrum in an Italian tertiary care hospital. J Inf Secur 51(5):383–389Google Scholar
- 12.Gunderson CG, Martinello RA (2012) A systematic review of bacteraemia in cellulitis and erysipelas. J Inf Secur 64(2):148–155Google Scholar
- 13.Pulido-Cejudo A, Guzmán-Gutierrez M, Jalife-Montaño A, Ortiz-Covarrubias A, Martínez-Ordaz JL, Noyola-Villalobos HF et al (2017) Management of acute bacterial skin and skin structure infections with a focus on patients at high risk of treatment failure. Ther Adv Infect Dis 4(5):143–161Google Scholar
- 14.Halilovic J, Heintz BH, Brown J (2012) Risk factors for clinical failure in patients hospitalized with cellulitis and cutaneous abscess. J Inf Secur 65(2):128–134Google Scholar
- 15.Figtree M, Konecny P, Jennings Z, Goh C, Krilis SA, Miyakis S (2010) Risk stratification and outcome of cellulitis admitted to hospital. J Inf Secur 60(6):431–439Google Scholar